Genentech (OTCQX:RHHBY) is presenting positive results from the Phase III IMvigor130 study evaluating Tecentriq (atezolizumab) today at the European Society for Medical Oncology Congress.
The company says IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer.
Genentech says the Tecentriq combination reduced the risk of disease worsening or death (progression-free survival) compared with chemotherapy alone.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.